• 1. Investigation of a tetrahydroisoquinoline scaffold as dual-action steroid sulfatase inhibitors generated by parallel solid-phase synthesis
  étienne Ouellet,René Maltais,Charles Ouellet,Donald Poirier Med. Chem. Commun. 2013 4 681
• 2. Highly selective production of benzylamine from benzonitrile on metal-supported catalysts
  Darío J. Segobia,Andrés F. Trasarti,Carlos R. Apesteguía React. Chem. Eng. 2021 6 2181
• 3. 78. A novel method of cyanoethylation. Part IV. Substitution effects
  R. J. Bates,J. Cymerman-Craig,M. Moyle,R. J. Young J. Chem. Soc. 1956 388
• 4. Enhanced reduction of C–N multiple bonds using sodium borohydride and an amorphous nickel catalyst
  Shouxin Liu,Yihua Yang,Xiaoli Zhen,Junzhang Li,Huimin He,Juan Feng,Andrew Whiting Org. Biomol. Chem. 2012 10 663
• 5. Photocatalytic hydrodenitrogenation of aromatic cyanides on TiO2 loaded with Pd nanoparticles
  Yoshitsune Sugano,Keisuke Fujiwara,Yasuhiro Shiraishi,Satoshi Ichikawa,Takayuki Hirai Catal. Sci. Technol. 2013 3 1718

• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Research Brief on N-Benzylethylamine (CAS: 14321-27-8): Recent Advances and Applications in Chemical Biology and Pharmaceutical Sciences

N-Benzylethylamine (CAS: 14321-27-8) is a structurally simple yet pharmacologically significant compound that has garnered increasing attention in the fields of chemical biology and pharmaceutical research. This secondary amine, characterized by its benzyl and ethyl substituents, serves as a versatile scaffold for the synthesis of bioactive molecules and has been implicated in various therapeutic applications. Recent studies have explored its potential as a precursor for novel drug candidates, particularly in the realms of central nervous system (CNS) modulation and antimicrobial agents.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of N-Benzylethylamine derivatives as selective serotonin receptor modulators. The research team synthesized a series of analogs, demonstrating that subtle modifications to the benzyl moiety could significantly enhance binding affinity to 5-HT2A receptors while minimizing off-target effects. These findings suggest promising avenues for developing next-generation antipsychotic medications with improved efficacy and safety profiles.

In the field of antimicrobial research, a recent breakthrough published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that N-Benzylethylamine-based compounds exhibit potent activity against multidrug-resistant Staphylococcus aureus strains. The study employed computational docking simulations to elucidate the molecular interactions between these compounds and bacterial efflux pump proteins, providing crucial insights for combating antibiotic resistance.

From a chemical biology perspective, N-Benzylethylamine has emerged as a valuable tool compound for studying enzyme inhibition mechanisms. A 2024 Nature Chemical Biology publication detailed its use as a competitive inhibitor of monoamine oxidase B (MAO-B), with crystallographic data revealing unexpected allosteric binding modes that challenge conventional understanding of MAO-B substrate recognition.

The compound's pharmacokinetic properties have also been the subject of recent investigation. Advanced analytical techniques, including LC-MS/MS and PET imaging, have enabled researchers to track N-Benzylethylamine distribution in vivo, yielding important data about its blood-brain barrier permeability and metabolic stability. These studies, published in Drug Metabolism and Disposition (2023), provide critical parameters for future drug development efforts.

Emerging applications in radiopharmaceuticals have further expanded the utility of N-Benzylethylamine derivatives. A 2024 study in the Journal of Nuclear Medicine demonstrated the successful incorporation of fluorine-18 labeled analogs for positron emission tomography (PET) imaging of dopamine receptors, offering new diagnostic tools for neurodegenerative disorders.

Despite these advances, challenges remain in optimizing the therapeutic index of N-Benzylethylamine-based compounds. Current research efforts, as highlighted in a recent ACS Pharmacology & Translational Science review (2024), are focusing on structure-activity relationship studies to improve selectivity and reduce potential cardiovascular side effects associated with this chemical scaffold.

The growing body of research on N-Benzylethylamine (14321-27-8) underscores its importance as both a pharmacological tool and a promising lead structure for drug discovery. As synthetic methodologies continue to advance and our understanding of its biological interactions deepens, this compound is poised to play an increasingly significant role in addressing unmet medical needs across multiple therapeutic areas.

• 15429-17-1(N-Benzyl-1-(3-methylphenyl)methanamine Hydrochloride)
• 34235-31-9(1,3-Benzenedimethanamine,N-[[3-(aminomethyl)phenyl]methyl]- (9CI))
• 39099-13-3(N-(4-Methylbenzyl)ethanamine)
• 84227-70-3({4-(diethylamino)methylphenyl}methanamine)
• 25790-41-4(1,4-Benzenedimethanamine,N1,N4-bis(phenylmethyl)-)
• 85567-29-9(1,4-Benzenedimethanamine,N-[[4-(aminomethyl)phenyl]methyl]- (9CI))
• 88358-66-1(Benzenemethanamine,N-(phenylmethyl)-, hydrobromide (1:1))
• 103-49-1(Dibenzylamine)
• 98180-43-9(4,4'-dimethyldibenzylamine)
• 116530-03-1( )